Immunovant price target raised to $26 from $21 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Immunovant to $26 from $21 and keeps a Buy rating on the shares. The analyst adjusted the model following the recent announcement that the company is now pursuing warm autoimmune hemolytic anemia with IMVT-1402 instead of batoclimab. The firm believes Graves’ disease will be a better indication for the company to pursue with this molecule.